» Articles » PMID: 34496895

Quality of Life and Treatment-related Burden During Ocular Proton Therapy: a Prospective Trial of 131 Patients with Uveal Melanoma

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2021 Sep 9
PMID 34496895
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Proton beam therapy is a well-established treatment option for patients with uveal melanoma (UM). The treatment procedure, in general, includes placing radiopaque clips to ensure exact eye-positioning during radiotherapy, followed by the delivery of proton irradiation. The short-term burden associated with proton therapy in patients with UM has rarely been addressed. In this prospective study, we investigated the physiological and psychological aspects of proton therapy that might affect the well-being of patients during the different stages of treatment.

Methods: During the treatment procedure, we conducted longitudinal assessments of the Quality of life (QOL), organ-specific symptoms, and psychological aspects in patients with UM with three questionnaires (EORTC QLQ-C30, EORTC QLQ-OPT30, and GAD-7). Patients completed questionnaires before clip surgery (T0), before proton therapy (T1), after completing treatment (T2), and three months after treatment completion (T3). We also collected data on tumor characteristics and socio-demographics to identify potential risk factors associated with high treatment burdens.

Results: We prospectively included 131 consecutive patients. Questionnaire data showed a significant, temporary decline in global QOL and an increase in eye-related symptoms, as a result of the clip surgery (T0-T1). After treatment completion (T2), global QOL improved gradually, and none of the eye-related symptoms significantly deteriorated over the course of proton therapy. The global QOL returned to baseline levels three months after treatment (T3). We identified baseline anxiety as an independent risk factor for experiencing an acute treatment-related burden. Furthermore, we found interactions between GAD7 and patient sex showing that anxiety had a more pronounced effect on QOL outcome in female patients.

Conclusion: The short-term treatment-related burden of ocular proton therapy appeared to be largely associated with the preceding clip surgery, rather than the irradiation procedure. We found that anxiety was strongly associated with experiencing QOL issues during the treatment procedure. Our findings could contribute to the development of future strategies for improving the treatment process and psycho-oncologic patient care.

Citing Articles

Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France - protocol of a prospective observational mixed-method study.

Muller A, Dolbeault S, Piperno-Neumann S, Clerc M, Jarry P, Cassoux N BMC Psychiatry. 2024; 24(1):812.

PMID: 39548476 PMC: 11566303. DOI: 10.1186/s12888-024-06265-2.


Proton Therapy in Uveal Melanoma.

Chan A, Lin H, Yacoub I, Chhabra A, Choi J, Simone 2nd C Cancers (Basel). 2024; 16(20).

PMID: 39456591 PMC: 11506608. DOI: 10.3390/cancers16203497.


Robot-assisted system for non-invasive wide-range flexible eye positioning and tracking in particle radiotherapy.

Shi D, Ming X, Wang K, Wang X, Sheng Y, Jia S Phys Eng Sci Med. 2024; 47(4):1415-1423.

PMID: 38922382 DOI: 10.1007/s13246-024-01453-6.


Quality of life among people with eye cancer: a systematic review from 2012 to 2022.

Huang Y, Guo Y Health Qual Life Outcomes. 2024; 22(1):3.

PMID: 38185647 PMC: 10773080. DOI: 10.1186/s12955-023-02219-6.


Depression and anxiety in patients with uveal melanoma undergoing curative proton treatment-A prospective study.

Rabsahl C, Boehmer D, Boeker A, Gauger U, Goerling U, Gollrad J Cancer Rep (Hoboken). 2023; 6(4):e1780.

PMID: 36639921 PMC: 10075284. DOI: 10.1002/cnr2.1780.


References
1.
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

2.
Wyder S, Hennings F, Pezold S, Hrbacek J, Cattin P . With Gaze Tracking Toward Noninvasive Eye Cancer Treatment. IEEE Trans Biomed Eng. 2015; 63(9):1914-1924. DOI: 10.1109/TBME.2015.2505740. View

3.
Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

4.
Via R, Hennings F, Fattori G, Pica A, Lomax A, Weber D . Technical Note: Benchmarking automated eye tracking and human detection for motion monitoring in ocular proton therapy. Med Phys. 2020; 47(5):2237-2241. DOI: 10.1002/mp.14087. View

5.
Lowe B, Decker O, Muller S, Brahler E, Schellberg D, Herzog W . Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008; 46(3):266-74. DOI: 10.1097/MLR.0b013e318160d093. View